{"product_id":"chrs-marketing-mix","title":"(CHRS) Coherus Oncology, Inc. Marketing Mix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Coherus Oncology, Inc. 4P's Marketing Mix Analysis summarizes the company’s product offerings, pricing approach, distribution channels, and promotional tactics to show how it competes in oncology markets; the page includes a real preview\/sample of the analysis so you can evaluate style and content. Purchase the full version to receive the complete, ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLOQTORZI, PD-1 inhibitor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLOQTORZI is Coherus Oncology, Inc.’s lead branded oncology product and the core of its pivot into cancer care. It is a next-generation PD-1 inhibitor for solid tumors, including nasopharyngeal carcinoma, and is the only FDA-approved treatment in the U.S. for recurrent or metastatic NPC with gemcitabine and cisplatin. In 2024, Coherus Oncology, Inc. reported LOQTORZI net product revenue of about $7 million.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUDENYCA, pegfilgrastim biosimilar\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUDENYCA, a pegfilgrastim biosimilar to Neulasta, is a long-acting G-CSF used as a 6 mg once-per-cycle dose to help neutrophil recovery after chemotherapy and cut febrile neutropenia risk. It gives Coherus Oncology, Inc. a steady supportive-care revenue base, with biosimilar pricing and hospital\/clinic adoption driving access. In 2024, Coherus still cited UDENYCA as a core oncology franchise asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYUSIMRY, adalimumab biosimilar\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eYUSIMRY is Coherus Oncology, Inc.'s adalimumab biosimilar to Humira, used for rheumatoid arthritis, psoriasis, and Crohn’s disease. As a lower-cost biologic in the $20 billion-plus adalimumab market, it helps widen the Company beyond oncology into immune-mediated care. Its reach supports a broader prescriber base and diversifies revenue risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCIMERLI, ranibizumab biosimilar\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCIMERLI, Coherus Oncology, Inc.’s ranibizumab biosimilar, targets the same VEGF-A pathway as Lucentis and is used for wet AMD, diabetic macular edema, and diabetic retinopathy. As a retina product, it gives Coherus a foothold in an ophthalmology market that treats millions of patients and relies on repeat intravitreal dosing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProduct: Lucentis biosimilar\u003c\/li\u003e\n\u003cli\u003eUse: wet AMD, DME, DR\u003c\/li\u003e\n\u003cli\u003eForm: intravitreal injection\u003c\/li\u003e\n\u003cli\u003eValue: retina-market presence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePipeline, 4 named immunotherapy programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCoherus Oncology, Inc.’s 4-program pipeline is the main post-biosimilar growth engine: Casdozokitug, CHS-114, CHS-1000, and GSK4381562. These immunotherapy assets target immune checkpoints and the tumor microenvironment, aiming to expand beyond the company’s biosimilar base, which delivered $281.4 million in 2025 net product revenue. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e4 named immunotherapy programs\u003c\/li\u003e\n\u003cli\u003eCheckpoint and TME targets\u003c\/li\u003e\n\u003cli\u003ePost-biosimilar growth driver\u003c\/li\u003e\n\u003cli\u003e2025 net product revenue: $281.4M\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCoherus Shifts Toward Oncology-Driven Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCoherus Oncology, Inc.’s Product mix is led by LOQTORZI, its FDA-approved PD-1 therapy for recurrent or metastatic NPC, plus UDENYCA, YUSIMRY, and CIMERLI as revenue-supporting biosimilars. The shift is still early, but the mix is more oncology-focused than before. In 2025, net product revenue was $281.4 million.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLOQTORZI\u003c\/td\u003e\n\u003ctd\u003eLead branded therapy\u003c\/td\u003e\n\u003ctd\u003e$7M 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilars\u003c\/td\u003e\n\u003ctd\u003eRevenue base\u003c\/td\u003e\n\u003ctd\u003e$281.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise, company-specific 4P’s analysis of Coherus Oncology, Inc.’s product, pricing, place, and promotion strategy for clear market insight.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eTurns Coherus Oncology’s 4Ps into a clear snapshot that quickly relieves analysis overload.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable bibliography linking each Coherus Oncology claim to primary industry reports, regulatory filings, and trusted datasets for faster, defensible decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePlace\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU.S. headquarters, Redwood City, California\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCoherus Oncology, Inc. is headquartered in Redwood City, California, and the U.S. is its core operating market. That Bay Area base supports corporate, regulatory, and commercial work close to major life-science talent and investors. Redwood City sits about 25 miles south of San Francisco, which helps speed hiring, partner access, and U.S. market execution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty oncology distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn 2024, LOQTORZI was distributed through oncology-focused channels, with access centered on cancer clinics and infusion sites, not mass retail. This buy-and-bill model fits specialist prescribing, where treatment starts in supervised settings and payer handling stays tied to oncology practices. The channel is built for physician demand, prior auth, and specialty support, which suits a niche, high-acuity cancer drug.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty pharmacy and buy-and-bill\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCoherus Oncology, Inc. sells its biosimilars through specialty pharmacy and buy-and-bill, the two main reimbursement paths for injectable biologics. This matters because payers and providers decide access and payment at the point of care, where medical-benefit claims are processed. In 2025, Coherus reported net product revenue of about $152 million, showing how channel mix directly supports sales execution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRetina and rheumatology sites of care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCIMERLI and YUSIMRY are placed in specialist outpatient settings, so Coherus Oncology reaches patients where retina and rheumatology treatment decisions are made. Retina practices, rheumatology clinics, and related infusion sites are the key access points, and the company’s place strategy follows the treating physician.\u003c\/p\u003e\n\u003cp\u003eThis model fits high-touch biologic care, where the prescriber, site of care, and payer all shape access and uptake. For Coherus Oncology, that means the sales effort is built around specialty offices and infusion networks, not broad retail distribution.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialist outpatient sites drive access.\u003c\/li\u003e\n\u003cli\u003eRetina and rheumatology are core channels.\u003c\/li\u003e\n\u003cli\u003eInfusion sites support treatment delivery.\u003c\/li\u003e\n\u003cli\u003ePlace strategy follows the prescriber.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner-led reach, Junshi, Bioeq, Genentech, Surface, Vaccinex\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCoherus Oncology, Inc. uses 5 named partners, Junshi, Bioeq, Genentech, Surface, and Vaccinex, to extend reach beyond its own sales force. These deals split work across development, manufacturing, and regional access, so Coherus can scale without building a full direct network in every market.\u003c\/p\u003e\n\u003cp\u003eThis model lowers fixed selling costs and shifts more execution risk to partners, which matters when oncology launches need speed and capital discipline. The mix also supports faster market entry in multiple geographies, instead of depending only on Coherus-owned distribution.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e5 partner links expand reach\u003c\/li\u003e\n\u003cli\u003eShared development cuts cost load\u003c\/li\u003e\n\u003cli\u003ePartner access speeds regional entry\u003c\/li\u003e\n\u003cli\u003eLess need for direct sales buildout\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Channels Drive Coherus Oncology’s $152M 2025 Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCoherus Oncology, Inc. places its products through specialist oncology, retina, rheumatology, and infusion settings, not mass retail. This keeps access tied to prescribers, prior auth, and site-of-care decisions. In 2025, net product revenue was about $152 million, showing the channel mix was central to sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePlace factor\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore channels\u003c\/td\u003e\n\u003ctd\u003eSpecialty pharmacy, buy-and-bill\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey sites\u003c\/td\u003e\n\u003ctd\u003eOncology, retina, rheumatology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet product revenue\u003c\/td\u003e\n\u003ctd\u003eAbout $152 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eCoherus Oncology, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Coherus Oncology 4P's Marketing Mix analysis you’ll receive instantly after purchase—complete, editable, and ready to use for strategy, pricing, product positioning, and promotional planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePromotion\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJunshi co-commercialization for LOQTORZI\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLOQTORZI is co-commercialized with Junshi Biosciences, giving Coherus Oncology, Inc. shared launch support and scientific messaging. The product won its first U.S. FDA approvals in 2023, including nasopharyngeal carcinoma and esophageal squamous cell carcinoma, which sharpened the launch story. The alliance also splits development and market-expansion work across 2 partners.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology field force and medical affairs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCoherus Oncology, Inc. uses specialist sales teams and medical affairs to reach oncologists and other specialist prescribers, not mass consumers. This fits a market where treatment choices lean on trial data, guideline support, and payer access. The model is built for high-touch, evidence-led promotion across a narrow, high-value prescriber base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical congress data\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCoherus Oncology, Inc. uses medical congresses and scientific meetings to share clinical data on its oncology products and pipeline assets, which is key in a market where peer review drives trust. In 2025, major congresses like ASCO and ESMO drew tens of thousands of clinicians and researchers, giving the Company broad reach with physicians and payers. Strong congress readouts can support adoption, pricing, and future trial interest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHCP education for biosimilars\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCoherus Oncology, Inc. uses HCP education to cut adoption friction for UDENYCA, YUSIMRY, and CIMERLI by stressing biosimilarity, access, and reference-product comparability. The message fits three biosimilars across oncology, immunology, and ophthalmology, where physician and pharmacy buy-in drives uptake.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBiosimilarity first\u003c\/li\u003e\n\u003cli\u003eAccess and coverage matter\u003c\/li\u003e\n\u003cli\u003eEducates physicians and pharmacies\u003c\/li\u003e\n\u003cli\u003eSupports 3-product portfolio\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePayer access and formulary messaging\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCoherus Oncology, Inc. frames payer access and formulary messaging to hospitals, payers, and integrated delivery systems around clinical value and clean reimbursement fit. In specialty drugs, where access can decide uptake, this message helps reduce coverage friction and speed adoption.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets payers and hospital systems\u003c\/li\u003e\n\u003cli\u003eFocuses on clinical value\u003c\/li\u003e\n\u003cli\u003eSupports formulary placement\u003c\/li\u003e\n\u003cli\u003eFits specialty drug buying\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCoherus Pushes LOQTORZI with Dual-Partner Promotion and ASCO\/ESMO Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCoherus Oncology, Inc. promotes LOQTORZI through a co-commercialization model with Junshi Biosciences, which shares launch support and scientific messaging across 2 partners.\u003c\/p\u003e\n\u003cp\u003eThe Company leans on specialist sales, medical affairs, and congress data, with 2025 ASCO and ESMO drawing tens of thousands of clinicians and researchers.\u003c\/p\u003e\n\u003cp\u003ePromotion is aimed at oncologists, payers, and hospitals, with HCP education focused on biosimilarity, access, and reimbursement fit.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCongresses\u003c\/td\u003e\n\u003ctd\u003eTens of thousands attended\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCo-promotion\u003c\/td\u003e\n\u003ctd\u003e2 partners\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget\u003c\/td\u003e\n\u003ctd\u003eSpecialists and payers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePrice\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty biologic pricing for LOQTORZI\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLOQTORZI is priced like a branded specialty biologic, with IV use in oncology clinics and a narrow U.S. label in 2 approved indications, so Coherus Oncology can support higher revenue per treated patient.\u003c\/p\u003e\n\u003cp\u003eIts pricing fits limited patient pools and specialist prescribing, where access, infusion, and payer controls matter more than broad retail demand.\u003c\/p\u003e\n\u003cp\u003eThat model helps Coherus Oncology defend gross value per dose, even if total volume stays small versus mass-market drugs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosimilar discounting for UDENYCA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUDENYCA uses biosimilar discounting to win access, pricing below Neulasta to fit payer and protocol budgets. Neulasta’s pegfilgrastim market has long carried premium list pricing, so even a modest double-digit discount can shift formulary placement. That lower price is a core launch lever for Coherus Oncology, Inc., not a margin afterthought.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosimilar discounting for YUSIMRY\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eYUSIMRY, Coherus Oncology, Inc.’s adalimumab biosimilar, is priced to undercut Humira and drive switch demand in a market where Humira’s U.S. list price has been about $6,922 for a 2-pen pack. Coherus has used deep discounting to improve payer access and patient affordability, which matters in crowded inflammatory-disease therapy lines. Lower net price can speed formulary wins and adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBiosimilar discounting for CIMERLI\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCIMERLI uses biosimilar pricing against Lucentis, so Coherus Oncology, Inc. can lean on lower unit cost plus access terms when retina groups compare total treatment cost. In ophthalmology, buyers look at price, reimbursement, and buy-and-bill fit together, and that helps CIMERLI move into practice purchasing pathways.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCuts price vs Lucentis\u003c\/li\u003e\n\u003cli\u003eSupports payer access terms\u003c\/li\u003e\n\u003cli\u003eFits retina buying decisions\u003c\/li\u003e\n\u003cli\u003eHelps pathway adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eReimbursement, rebates, and copay support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePricing at Coherus Oncology, Inc. hinges on payer contracts, prior auth, and reimbursement economics, not list price. In specialty drugs, gross-to-net deductions can top 30%, so rebates and copay help can lift net access while keeping consumer retail pricing out of the model.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNegotiate payer access first\u003c\/li\u003e\n\u003cli\u003eUse rebates to cut net price\u003c\/li\u003e\n\u003cli\u003eSupport copays to aid uptake\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCoherus Pricing: Premium Biologic Value, Biosimilar Discount Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCoherus Oncology, Inc. prices LOQTORZI as a specialty biologic in 2 approved U.S. indications, so value per treated patient stays high even with low volume.\u003c\/p\u003e\n\u003cp\u003eUDENYCA, YUSIMRY, and CIMERLI use biosimilar discounting to win payer access, with YUSIMRY set below Humira’s about $6,922 list price for a 2-pen pack.\u003c\/p\u003e\n\u003cp\u003ePrice here is mostly about formulary wins, prior auth, and net rebates, not retail demand.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003ePrice role\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLOQTORZI\u003c\/td\u003e\n\u003ctd\u003ePremium specialty pricing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYUSIMRY\u003c\/td\u003e\n\u003ctd\u003eDeep Humira discount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234258067721,"sku":"chrs-marketing-mix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/chrs-marketing-mix.webp?v=1785714848","url":"https:\/\/dcfanalyst.com\/products\/chrs-marketing-mix","provider":"DCF Analyst","version":"1.0","type":"link"}